A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Public ClinicalTrials.gov record NCT05947851. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Study identification
- NCT ID
- NCT05947851
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 735 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 8, 2023 (Actual)
- Primary completion
- Jun 1, 2032 (Estimated)
- Completion
- Jul 1, 2035 (Estimated)
- Last update posted
- Oct 15, 2026
2023 – 2035
United States locations
- U.S. sites
- 25
- U.S. states
- 19
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group ( Site 5405) | Springdale | Arkansas | 72762 | Recruiting |
| MemorialCare Health System - Long Beach Medical Center ( Site 5421) | Long Beach | California | 90806 | Recruiting |
| Clermont Oncology Center ( Site 5430) | Clermont | Florida | 34711 | Recruiting |
| Memorial Hospital West ( Site 5410) | Pembroke Pines | Florida | 33028 | Recruiting |
| Fort Wayne Medical Oncology and Hematology ( Site 5444) | Fort Wayne | Indiana | 46804 | Recruiting |
| Center for Cancer and Blood Disorders ( Site 5439) | Bethesda | Maryland | 20817 | Recruiting |
| Avera Cancer Institute - Marshall ( Site 5462) | Marshall | Minnesota | 56258 | Recruiting |
| Hattiesburg Clinic Hematology/Oncology ( Site 5416) | Hattiesburg | Mississippi | 39401 | Recruiting |
| MidAmerica Cancer Care, LLC ( Site 5426) | Kansas City | Missouri | 64132 | Recruiting |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 5433) | Billings | Montana | 59102 | Recruiting |
| Renown Regional Medical Center-Renown Health Medical Oncology ( Site 5434) | Reno | Nevada | 89502 | Recruiting |
| Atlantic Health System Morristown Medical Center ( Site 5445) | Morristown | New Jersey | 07960 | Recruiting |
| New York Oncology Hematology, P.C. ( Site 5453) | Albany | New York | 12208 | Recruiting |
| Oregon Health and Science University ( Site 5425) | Portland | Oregon | 97239-3011 | Recruiting |
| Avera Cancer Institute - Aberdeen ( Site 5458) | Aberdeen | South Dakota | 57401 | Recruiting |
| Avera Cancer Institute - Mitchell ( Site 5461) | Mitchell | South Dakota | 57301 | Recruiting |
| Avera Cancer Institute - Pierre ( Site 5460) | Pierre | South Dakota | 57501 | Recruiting |
| Avera Cancer Institute- Research ( Site 5437) | Sioux Falls | South Dakota | 57105 | Recruiting |
| Avera Cancer Institute - Yankton ( Site 5459) | Yankton | South Dakota | 57078 | Recruiting |
| PatientCare Clinical Research LLC ( Site 5435) | Sugar Land | Texas | 77479 | Recruiting |
| University of Virginia Cancer Center ( Site 5402) | Charlottesville | Virginia | 22903 | Recruiting |
| Vista Oncology ( Site 5449) | Olympia | Washington | 98506 | Recruiting |
| Medical Oncology Associates, PS ( Site 5406) | Spokane | Washington | 99208 | Recruiting |
| West Virginia University ( Site 5447) | Morgantown | West Virginia | 26506 | Recruiting |
| University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423) | Madison | Wisconsin | 53792 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05947851, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05947851 live on ClinicalTrials.gov.